Scholar Rock gains on smaller Q2 net loss; FDA review progresses
06/08/2026 12:45
BUZZ-Scholar Rock gains on smaller Q2 net loss; FDA review progresses ** Shares of Scholar Rock SRRK.O rise 9.69% to $52.51 premarket
** Q2 net loss per share was $0.84 vs loss of $0.98 per share last year
** Co says FDA review of the application of its spinal muscular atrophy drug continues to advance with two fill-finish facilities, representing two independent paths to a decision by September 30
** Adds co is prepared for U.S. launch of the drug, apitegromab, immediately upon FDA approval; Ample supply available for commercialization
** As of June 30, 2026, SRRK had cash, cash equivalents, and marketable securities of $492.1 million
** Up to last close, stock up ~9% YTD
(Reporting by Sriparna Roy in Bengaluru)
Recent news on Scholar Rock Holding
See all newsBrief: Scholar Rock Reports New Employee Inducement Grants
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (Maa) To European Medicines Agency (EMA) For Treatment Of Children And Adults With Spinal Muscular Atrophy (SMA)
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up